MRPL50P2

Across TCGA pan-cancer cohorts, MRPL50P2 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated MRPL50P2 data layer.

The strongest signal is observed in sarcoma (SARC), where higher MRPL50P2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MRPL50P2 expression acts as an unfavorable survival marker, although some lineages such as SARC and COAD show a favorable association.

SARC, UCEC, and ACC are the cancer types where MRPL50P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Tertile	All	0.841	0.574	.007	36	view →
UCEC	DFS	Tertile	II,III,IV	0.617	0.763	.026	30	view →
ACC	DFS	Quartile	III,IV	0.328	0.637	.010	30	view →
COAD	DFS	Tertile	All	0.884	0.647	.008	27	view →
UVM	OS	Tertile	III,IV	0.234	0.762	.004	27	view →
STAD	OS	Tertile	III,IV	0.493	0.229	.008	26	view →
CESC	OS	Tertile	All	0.906	0.763	.010	18	view →
UCS	DFS	Tertile	All	0.152	0.489	.003	18	view →
MESO	OS	Median	IV	0.639	0.249	.013	9	view →
SKCM	OS	Tertile	IV	0.182	0.654	.021	9	view →
BRCA	DFS	Tertile	IV	0.945	0.565	.027	6	view →
LGG	DFS	Quartile	All	0.296	0.424	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

MRPL50P2–SARC (DFS)

Open the SARC breakdown →